Certara Inc
NASDAQ:CERT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Certara Inc
NASDAQ:CERT
|
US |
|
S
|
Stroeer SE & Co KgaA
SWB:SAX
|
DE |
|
N
|
Novartis AG
BMV:NVSN
|
CH |
|
D
|
Dillard's Inc
XBER:DL7A
|
US |
|
Richards Group Inc
TSX:RIC
|
CA |
|
A
|
Acen Corp
XPHS:ACEN
|
PH |
|
C
|
Coloplast A/S
F:CBH
|
DK |
|
A
|
Activision Blizzard Inc
XBER:AIY
|
US |
|
China Literature Ltd
HKEX:772
|
CN |
|
TBS Holdings Inc
TSE:9401
|
JP |
|
Pfizer Inc
NYSE:PFE
|
US |
Certara Inc
Certara helps drug makers use software and scientific consulting to design and test medicines before and during clinical development. Its main products are biosimulation software tools, data and modeling platforms, and expert services that help customers predict how a drug will behave in the body and choose better trial designs. Its customers are pharmaceutical companies, biotech firms, and some regulators and academic groups that work on drug development. Certara makes money by selling software licenses and subscriptions, plus consulting and project work for specific development programs. The software usually sits inside a drug company’s research workflow, while the services help teams apply the models to real drug candidates. What makes Certara different is that it is not trying to sell the drug itself or run the trials end to end. It sells tools and expertise that help make drug development faster, more informed, and less wasteful. That gives it a role as a technical partner in the life sciences value chain, especially where companies need to understand dose, safety, and trial design before spending heavily on large studies.
Certara helps drug makers use software and scientific consulting to design and test medicines before and during clinical development. Its main products are biosimulation software tools, data and modeling platforms, and expert services that help customers predict how a drug will behave in the body and choose better trial designs.
Its customers are pharmaceutical companies, biotech firms, and some regulators and academic groups that work on drug development. Certara makes money by selling software licenses and subscriptions, plus consulting and project work for specific development programs. The software usually sits inside a drug company’s research workflow, while the services help teams apply the models to real drug candidates.
What makes Certara different is that it is not trying to sell the drug itself or run the trials end to end. It sells tools and expertise that help make drug development faster, more informed, and less wasteful. That gives it a role as a technical partner in the life sciences value chain, especially where companies need to understand dose, safety, and trial design before spending heavily on large studies.
Revenue: Certara reported first-quarter revenue of $106.9 million, up 1% year over year, with software strength partly offset by weaker services and regulatory writing.
Software rebound: Software revenue rose 7% to $49.7 million and software bookings increased 20%, with management saying performance was strong across all customer tiers.
Services softness: Services revenue fell 4% and services bookings dropped 14%, with management pointing to mixed MIDD execution and softness in regulatory services.
Strategic reset: The company closed the divestiture of its regulatory writing and medical writing business and is reorganizing around two growth areas: MID3 and ACE.
AI push: Certara is building an AI-integrated platform, naming a Chief AI Officer and announcing a collaboration with NVIDIA to speed computationally heavy workflows.
Outlook: Full-year 2026 revenue guidance was updated to $395 million to $405 million, with software expected to grow at or above the high end of the 0% to 4% range and services toward the low end.
